CTRI/2023/08/056186尚未招募4 期
Efficacy and safety of Netarsudil 0.02% ophthalmic solution in primary angle closure glaucoma in a tertiary care institute, Hisar: Prospective interventional study. - Nil
Maharaja agrasen medical college0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Inclusion Criteria:
- •1. Patients of either sex of age > 40 years.
- •2. Clinically diagnosed patients of:
- •Primary angle closure glaucoma
- •3. Able to give informed consent and follow study instructions
排除标准
- •Exclusion Criteria:
- •1 Patients having known hypersensitivity to any component of the formulation.
- •2 Previous glaucoma surgery or refractive surgery.
- •3 Report of ocular injury in either eye.
- •4 Inability to come for regular follow up.
- •5 Ocular diseases with inflammation as a manifestation.
- •6 Use of systemic medication (steroids) that could affect the IOP.
研究者
相似试验
尚未招募
4 期
A clinical trial to evaluate efficacy of topical netarsudil in comparison to topical latanoprost in primary angle closure disease spectrumCTRI/2023/02/049928Advanced Eye Centre
已完成
3 期
Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular HypertensionGlaucomaOcular HypertensionNCT02246764Aerie Pharmaceuticals93
已完成
2 期
Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in JapanOpen Angle GlaucomaOcular HypertensionNCT03844945Aerie Pharmaceuticals215
已完成
3 期
Efficacy and Safety Study of Netarsudil 0.02% Ophthalmic Solution Compared to Ripasudil Hydrochloride Hydrate 0.4% Ophthalmic Solution in Japanese Subjects With Primary Open Angle Glaucoma or Ocular HypertensionPrimary Open Angle GlaucomaOcular HypertensionNCT04620135Aerie Pharmaceuticals245
已完成
3 期
Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular HypertensionOpen-angle GlaucomaOcular HypertensionNCT02558374Aerie Pharmaceuticals708